Zentalis Pharmaceuticals, Inc.
No enriched coverage for $ZNTL in the last 7 days.
No SEC Form 4 filings for $ZNTL in the last 30 days.
SAN DIEGO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on November 3, 2025, ...
SAN DIEGO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the ...
SAN DIEGO, Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on ...
